Evidence map›Paper›PMID 41847736›Full record

ArticleJournal of Zhejiang University. Science. B2026

Targeting

Yu Wu, Guomin Ju, Xueyu Zhou, Jian Wu, Shusen Zheng, Chuanhui Peng

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Journal of Zhejiang University. Science. B, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Yu WuDivision of Hepatobiliary and Pancreatic Surgery, Department of Surgery, The First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou 310003, China.
Guomin JuDivision of Hepatobiliary and Pancreatic Surgery, Department of Surgery, The First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou 310003, China.
Xueyu ZhouDepartment of Thyroid Surgery, The First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou 310003, China.
Jian WuDivision of Hepatobiliary and Pancreatic Surgery, Department of Surgery, The First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou 310003, China.
Shusen ZhengDivision of Hepatobiliary and Pancreatic Surgery, Department of Surgery, The First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou 310003, China. shusenzheng@zju.edu.cn.
Chuanhui PengDivision of Hepatobiliary and Pancreatic Surgery, Department of Surgery, The First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou 310003, China. peng_chuanhui@zju.edu.cn.

Funding

the Department of Science and Technology of Zhejiang Province, China 2023C03063the National Natural Science Foundation of China 82002925
6 · The paper itself

Abstract

Hepatocellular carcinoma (HCC) often requires targeted therapy and immunotherapy due to frequent delayed diagnosis. Sorafenib, the first targeted drug applied to treat HCC, has demonstrated a remarkable therapeutic effect in the clinic. However, its clinical application has been limited by drug resistance and the insufficient understanding of the relevant mechanism. Wilms' tumor 1-associated protein (WTAP), associated with tumor progression, remains unstated in sorafenib resistance. In this study,

Indexed as

Antineoplastic AgentsCarcinoma, HepatocellularCell Cycle ProteinsLiver NeoplasmsMAP Kinase Signaling SystemRNA Splicing FactorsSorafenibAnimalsCell Line, TumorDrug Resistance, NeoplasmFemaleHumansMaleMiceMice, NudeMolecular Docking SimulationAntineoplastic AgentsCell Cycle ProteinsRNA Splicing FactorsSorafenibWTAP protein, humanExtracellular signal-regulated kinase (ERK) pathwayHepatocellular carcinoma (HCC)Sorafenib resistanceWilms’ tumor 1-associated protein (WTAP)

Identifiers

PMID41847736
PMCPMC12996864

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.